Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Shanghai Henlius Biotech FCF Yield % Related Terms
Shanghai Henlius Biotech FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02696 vs VRTX, REGN, RVMD: FCF Yield % Comparison
For the Biotechnology subindustry, Shanghai Henlius Biotech's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Henlius Biotech FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanghai Henlius Biotech's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Shanghai Henlius Biotech's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Henlius Biotech (HKSE:02696) has a FCF Yield % of 0.31 as of Aug. 16, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Shanghai Henlius Biotech and its competitors. According to the industry distribution chart, Shanghai Henlius Biotech ranks #222 out of 1410 companies in the Biotechnology industry, placing it in the top 15.7%.
Is Shanghai Henlius Biotech's FCF Yield % too high?
Shanghai Henlius Biotech's current FCF Yield % is 0.31. Based on the distribution chart, Shanghai Henlius Biotech ranks #222 out of 1410 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Shanghai Henlius Biotech has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Henlius Biotech's FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Henlius Biotech ranks #222 out of 1410 companies for FCF Yield %. This places Shanghai Henlius Biotech in the top 16% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Shanghai Henlius Biotech and its competitors. Shanghai Henlius Biotech's current FCF Yield % is 0.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Henlius Biotech stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Henlius Biotech (HKSE:02696) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$30.91, compared to a current price of HK$67.30 — trading 117.7% above its estimated fair value. The current FCF Yield % is 0.31. Shanghai Henlius Biotech's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Shanghai Henlius Biotech (HKSE:02696), the current FCF Yield % is 0.31 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Henlius Biotech (HKSE:02696) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Henlius Biotech stock appears to be overvalued.
The current stock price of HK$67.30 is trading 117.7% above its estimated GF Value™ of HK$30.91.
GuruFocus considers Shanghai Henlius Biotech to be Significantly Overvalued.
Key valuation signals for HKSE:02696:
FCF Yield %: 0.31
GF Value™: HK$30.91 vs. price of HK$67.30 (117.7% above fair value)
No single metric tells the full story. See the HKSE:02696 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China, Asia Pacific (excluding Mainland China), North America, South America, Oceania, and Europe. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.
67GF Score
Get the complete analysis for HKSE:02696
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02696 has been successfully added to your 
